Dr.NateNeph said:Say what you would expect to see if you were wrong, before you look.
Correct, and worth adding that it is reversible. Nothing being described here is a one-way door, which changes how cautious it is reasonable to be.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Dr.NateNeph said:Say what you would expect to see if you were wrong, before you look.
Genuinely useful, thank you. I had the facts and not the framework. Printing the relevant bit and taking it with me.
Clinical perspective, offered as context rather than as advice. The useful move here is to separate what is established from what is widely repeated. Those two sets overlap less than the confident tone of most write-ups suggests, and the second set is where nearly all the disagreement on this board comes from.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemDr.RaviCardio said:The useful move here is to separate what is established from what is widely repeated.
Same pattern here, and in the same order. The detail I would add is minor and it is already implied above.
Dr.RaviCardio said:The useful move here is to separate what is established from what is widely repeated.
Coming at Dr.RaviCardio’s question from a different direction. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.